Jncyo3aiyvnrbwy7vwtvfwczh

Total Page:16

File Type:pdf, Size:1020Kb

Jncyo3aiyvnrbwy7vwtvfwczh Neuroendocrinal syndromes in gynecology (Shikhane syndrome, hyperandrogeny, hyperprolactinemia). 1.Relevance Sheehan's syndrome, also known as postpartum pituitary gland necrosis, is hypopituitarism (decreased functioning of the pituitary gland), caused by ischemic necrosis due to blood loss and hypovolemic shock during and after childbirth In a study of 1,034 symptomatic adults, Sheehan’s syndrome was found to be the sixth-most frequent etiology of growth hormone deficiency, being responsible for 3.1% of cases (versus 53.9% due to a pituitary tumor). Hyperandrogenemia (HA) describes the condition of a patient with increased production of a group of steroid hormones known as androgens, from the Greek prefix “andro” meaning “man.” While these hormones play a central role in male physiology, they are also present to a lesser degree in females, with the most predominant androgens including testosterone, dihydrotestosterone (DHT), androstenedione, dehydroepiandrosterone (DHEA), and dehydroepiandrosterone sulfate (DHEA-S). The overall incidence of HA in women is approximately 5%–10%, with polycystic ovarian syndrome (PCOS) accounting for approximately 80% of cases. In general, HA may be caused by exogenous medications, endogenous neoplasms, or via the nonneoplastic overproduction of androgens. Clinical signs of HA include acne, abnormal hair growth (hirsutism), and male pattern baldness (alopecia). Other signs of HA may also be present, including irregular menstrual cycles, virilization (deepening voice, enlarging clitoris, breast atrophy), or insulin resistance. Excessive upper lip hair in a third of women ages 14-45 Hyperprolactinemia may result in hypogonadism, infertility, and galactorrhea, or it may remain asymptomatic Testing for hyperprolactinemia is straightforward, owing to the ease of ordering a serum prolactin measurement. Accordingly, an evidence-based, cost-effective approach to management of this relatively common endocrine disorder is required. Prolactin acts to induce and maintain lactation of the primed breast. Nonpuerperal hyperprolactinemia is caused by lactotroph adenomas (prolactinomas), which account for approximately 40% of all pituitary tumors.. Bone loss occurs secondary to hyperprolactinemia-mediated sex steroid attenuation. Spinal bone density is decreased by approximately 25% in women with hyperprolactinemia and is not necessarily restored with normalization of prolactin levels. Modern knowledge about neuroendocrinological syndroms of the female reproductive system function, role of hormones and biological active substances are at the heart of gynecology. 2. Objectives (are described in the terminology of professional activity, taking into account the system of classification of the objectives of the respective levels of cognitive, emotional and psychomotor spheres): -To analyze the results of main methods of functional diagnostics in gynecology -To explain The levels of regulation of woman`s genital functions -To suggest tactics of management of patients with neuroendocrinological syndroms. -To classify mestrual disordes (irregularities) -To interpret the results of laboratory and instrumental examinations of the cervix, endometrium, ovaries, depending with fazes of MC, the clinical and biochemical, hormonal studies of blood, results of colpocytologycal examination -To draw a diagram scheme of menstrual cycle --To make the analysis of the methods of functional diagnosis in gynecology -To make up the models of clinical cases with various hormanal pathology in women of reproductive and premenopausal age. 3. The basic level of expertise, skills, abilities, required for learning the topic (interdisciplinary integration ) The name of the previous Acquired skills disciplines Normal Anatomy Structure of female genital organs. Topography of abdominal organs and pelvic organs. Histology Histological structure of the cervix, vulva and endometrium in normal and in pathological conditions. Notmal Physiology Physiological changes occurring in the hypothalamic- pituitary-ovarian system of women and target organs of the sex hormones action at different ages. Pathological Physiology Hormonal changes in the body during the menstrual cycle and disorders of the microbiota of the female reproductive system. Pharmacology Groups of medications that affect the function of the hypothalamus, pituitary gland, ovaries, adrenal glands; mechanism of pharmacological action of hormonal, hemostatic, anti-inflammatory, antiviral drugs. 4. Tasks for independent work in preparation for the lesson and in class. 4.1. The list of the major terms, parameters, characteristics to be acquired by a student to be prepared for the lesson The term Definition Adrenogenital syndrome (AGS) is congenital adrenal hyperplasia, female hermaphroditism, or advanced sexual development of the heterosexual type develops as a result of necrotic changes in the hypophysis, which appeared Sheehan’s syndrome against the background of a spasm or intravascular blood coagulation in the vessels of the adenohypophysis after hemorrhages and septic shock during delivery or abortion Hyperprolactinemia . distinct clinical entity and resulted in distinguishing prolactin-secreting tumors from nonfunctioning adenomas Female Sex steroid hormones luteonizing hormone (LH) prolactin follicle-stimulating hormone (FSH) estrogens progesterone Replacement hormonal therapy (RHT) is aimed at the prevention and recovery of metabolic disorders of the climacteric period. Hirsutism Increased Terminal Hair male- patterned growth in women Alopecia Female-Patterned Hair Loss (central hair thinning) Acne Vulgaris is a long-term skin disease that occurs when dead skin cells and oil from the skin clog hair follicles.Typical features of the condition include blackheads or whiteheads, pimples, oily skin, and possible scarring 4.2 Theoretical questions for the lesson: 1. Regulations mechanisms of menstruation at different levels. 2. Biologic action of sex hormones, hypophysis hormones and releasing hormones. 3. Basic levels of menstruation regulation and physical stages of their establishment. 4. Pathogenesis of menstrual disorders. 5. Pathogenesis of adrenogenital syndrome 6. Clinic of adrenogenital syndrome 7. Management of adrenogenital syndrome 8. Pathogenesis of Sheehan`s syndrome 9. Clinic of Sheehan`s syndrome 10. Management of Sheehan`s syndrome 11. Pathogenesis of hyperprolactinemia 12. Clinic of hyperprolactinemia 13. Management of hyperprolactinemia 4.3 Practical activities (tasks) to be performed on the lesson: To Describe the proposed changes in organs of women during menstrual cycle. To Evaluate proposed by instructor menstrual cycle, amount of blood loss during normal and pathologic menstrual cycle (anovulatory cycle, luteine phase insuffi-ciency). To analyze the results of main methods of functional diagnostics in gynecology To suggest tactics of management of patients with hormonal imbalance of female reproductive system. To classify mestrual disordes (irregularities) To interpret the results of laboratory and instrumental examinations of the cervix, endometrium, ovaries, depending with fazes of MC, the clinical and biochemical, hormonal studies of blood, results of colpocytologycal examination To draw a diagram scheme of menstrual cycle and chart of basal temperature To make up the models of clinical cases with various hormanal pathology in women of reproductive and premenopausal age. Adrenogenital Syndrome Adrenogenital syndrome (AGS) is congenital adrenal hyperplasia, female hermaphroditism, or advanced sexual development of the heterosexual type. It should be noted that the adrenal glands synthesize 3 main groups of steroids of different biological action: 1) mineralocorticoids; 2) glucocorticoids; 3) reticular zone hormones – androgens (strong – testosterone, weak – дегідроепіандростерон, dehydroepiandrosterone sulfate, androstenedione), and estradiol with estrone, a small quantity of which is also formed here. Etiology and pathogenesis. AGS is a consequence of congenital genetically conditioned deficiency of enzyme systems, which take part in the synthesis of adrenal steroid hormones. At that, by the feedback principle there increases ACTH formation in the adenohypophysis and the synthesis of cortisol precursors, which form androgens due to enzyme deficit. Symptoms and Signs A. General appearance 1. Muscular male body habitus (e.g. Shoulder girdle) 2. Android Obesity B. Miscellaneous Changes 1. Deepening of voice 2. Clitorimegaly 3. Increased Libido C. Menstrual irregularity 1. Amenorrhea 2. Infertility D. Endocrine changes 1. Hypertension 2. Hyperlipidemia 3. Glucose Intolerance E. Skin changes Congenital Adrenogenital Syndrome Adrenal malfunction has an intrauterine onset, almost simultaneous with the beginning of adrenal glands functioning as an endocrine gland. The clinicodiagnostic criteria: - karyotype 46,ХХ; - the signs of external genitals virilization (clitoromegaly, fusion of the large lips of pudendum, and urogenital sinus persistence – fusion of the two lower thirds of the vagina and urethra, which opens under the enlarged clitoris); - the ovaries and uterus are developed correctly; - advanced sexual development of the heterosexual type; - hypertrichosis; - in consequence of the anabolic action of androgens there takes place the rapid lengthwise growth of tubular bones, distribution of the muscular and fatty tissue by the male type. In girls with congenital AGS the body length reaches 150–155 cm till the age of 10–12 years, children do not grow any
Recommended publications
  • Spectrum of Benign Breast Diseases in Females- a 10 Years Study
    Original Article Spectrum of Benign Breast Diseases in Females- a 10 years study Ahmed S1, Awal A2 Abstract their life time would have had the sign or symptom of benign breast disease2. Both the physical and specially the The study was conducted to determine the frequency of psychological sufferings of those females should not be various benign breast diseases in female patients, to underestimated and must be taken care of. In fact some analyze the percentage of incidence of benign breast benign breast lesions can be a predisposing risk factor for diseases, the age distribution and their different mode of developing malignancy in later part of life2,3. So it is presentation. This is a prospective cohort study of all female patients visiting a female surgeon with benign essential to recognize and study these lesions in detail to breast problems. The study was conducted at Chittagong identify the high risk group of patients and providing regular Metropolitn Hospital and CSCR hospital in Chittagong surveillance can lead to early detection and management. As over a period of 10 years starting from July 2007 to June the study includes a great number of patients, this may 2017. All female patients visiting with breast problems reflect the spectrum of breast diseases among females in were included in the study. Patients with obvious clinical Bangladesh. features of malignancy or those who on work up were Aims and Objectives diagnosed as carcinoma were excluded from the study. The findings were tabulated in excel sheet and analyzed The objective of the study was to determine the frequency of for the frequency of each lesion, their distribution in various breast diseases in female patients and to analyze the various age group.
    [Show full text]
  • Lupus Mastitis
    Published online: 2021-07-31 SPECIAL SYMPOSIUM - BREAST Lupus mastitis - peculiar radiological and pathological features Abdul Majid Wani, Waleed Mohd Hussain, Mohamed I Fatani, Bothaina Abdul Shakour Department of Radiology, Hera General Hospital, Makkah-10513, Saudi Arabia Correspondence: Dr Abdul Majid Wani, Hera General Hospital, Makkah-105 13, Saudi Arabia, E-mail: [email protected] Abstract Lupus mastitis is a form of lupus profundus that is seen in patients with systemic lupus erythematosus. It usually presents as a swelling (or swellings) in the breasts, with or without pain. The condition is recurrent and progresses along with the underlying disease, with fat necrosis, calcification, fibrosis, scarring, and breast atrophy. Lupus mastitis is often confused with malignancy and lymphoma and, in our part of the world, with tuberculosis. Confusion is especially likely when it occurs in an unusual clinical setting. In this article, we present a case that presented with unique radiological, pathological, and clinical features. Awareness of the various manifestations of lupus mastitis is essential if unnecessary interventions such as biopsies and surgeries, and their consequences, are to be avoided. Key words: Biopsy; lupus mastitis; lupus profundus; mammography; fine needle aspiration cytology; systemic lupus erythematosus Introduction hospital) was present and the patient reported that she had received antituberculous medication for 1 month at that Systemic lupus erythematosus (SLE) is a multisystem, time. Two 1 × 1.5 cm lymph nodes were present in the left autoimmune disorder. Involvement of the subcutaneous axillary region. The left breast revealed multiple lumps, the fat was termed as lupus profundus by Iregang.[1] Lupus biggest being 4 × 3 cm in size.
    [Show full text]
  • Androgens and Mammary Ca Fer Ster 02
    FERTILITY AND STERILITY௡ VOL. 77, NO. 4, SUPPL 4, APRIL 2002 ANDROGEN EFFECTS ON Copyright ©2002 American Society for Reproductive Medicine Published by Elsevier Science Inc. FEMALE HEALTH Printed on acid-free paper in U.S.A. Androgens and mammary growth and neoplasia Constantine Dimitrakakis, M.D., Jian Zhou, M.D., and Carolyn A. Bondy, M.D. Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland Objective: Evaluation of current clinical, experimental, genetic, and epidemiological data pertaining to the role of androgens in mammary growth and neoplasia. Design: Literature review. Setting: National Institutes of Health. Subject(s): Recent, basic, clinical, and epidemiological studies. Intervention(s): None. Main Outcome Measure(s): Effects of androgens on mammary epithelial proliferation and/or breast cancer incidence. Result(s): Experimental data derived from rodents and cell lines provide conflicting results that appear be strain- and cell line–dependent. Epidemiologic studies have significant methodological limitations and provide inconclusive results. The study of molecular defects involving androgenic pathways in breast cancer is in its infancy. Clinical and nonhuman primate studies, however, suggest that androgens inhibit mammary epithelial proliferation and breast growth and that conventional estrogen treatment suppresses endogenous androgens. Conclusion(s): Abundant clinical evidence suggests that androgens normally inhibit mammary epithelial proliferation and breast growth. Suppression of androgens by conventional estrogen treatment may thus enhance estrogenic breast stimulation and possibly breast cancer risk. Clinical trials to evaluate the impact of combined estrogen and androgen hormone replacement regimens on mammary gland homeostasis are needed to address this issue. (Fertil Steril௡ 2002;77(Suppl 4):S26–33.
    [Show full text]
  • 1 BREAST-FEEDING and MATERNAL-CHILD HEALTH Learning
    BREAST-FEEDING AND MATERNAL-CHILD HEALTH 3 CE hours Learning objectives Discuss issues pertinent to breast-feeding. Review the anatomy of the breast. Describe the physiological functioning of the breast. Identify breast changes that occur during pregnancy. Explain how to deal with mastitis and breast engorgement. Discuss the benefits of breast-feeding for mother and child. Identify the economic benefits of breast-feeding. Identify the societal benefits of breast-feeding. Discuss the barriers to breast-feeding. Describe strategies for successful breast-feeding. Offer suggestions for successful breast-feeding in public. Introduction Chris is 32 years old and gave birth to her second child late last night. This morning, she tells Karen, her hospital roommate, that she is looking forward to breast-feeding her baby. Chris had a very positive experience breast-feeding her first child and she tells her roommate, in great detail, about the benefit to both mother and child of breast-feeding. As Chris is speaking, a visitor arrives. The visitor’s name is Lisa and she and Chris have been close friends for years. Karen hesitantly tells both women that she had a very difficult time trying to breast- feed her first child. “My breasts were so sore and I developed a terrible infection in them. I finally had to stop trying to breast-feed, so I don’t know if I should try again.” Both Chris and Lisa express their disapproval, telling Karen that she “had” to breast-feed, and if she cared about her baby, she would not hesitate. Karen becomes tearful. At this point, a nurse arrives and gently but firmly puts an end to the confrontation.
    [Show full text]
  • Androgens and Breast Cancer in Men and Women
    Androgens and Breast Cancer in Men and Women a,b, Constantine Dimitrakakis, MD * KEYWORDS Androgens Testosterone Breast cancer Hormone therapy Menopause Male breast cancer There has been increasing focus recently on the importance of androgens in human physiology. Supplementation of testosterone in women with hypoactive sexual desire disorder is an area of great interest at present.1 Testosterone treatment in physiologic doses seems to improve sexual desire, responsiveness, and frequency of sexual activity, while at the same time it exhibits favorable effects on bone in postmenopausal women.2 However, the risk-benefit ratio for such treatment remains unclear. Androgen receptors (AR) are found in virtually every tissue in women as well as in men, including breast, bone, and brain, indicating that androgens and their metabo- lites may play an important role in normal tissue homeostasis and possibly in pathol- ogies, such as breast cancer, osteoporosis, decreased libido, and cognitive decline. A continuing area of concern is the notion that excess androgen exposure may increase the risk of breast cancer.3 Over the past decade, there have been major advances in our understanding of the sources of endogenous sex steroids acting on mammary epithelium with the identifi- cation of tissue-specific expression of steroidogenic enzymes capable of converting circulating prohormones, such as dehydroepiandrosterone (DHEA), into potent andro- gens or estrogens. In addition, there have been great strides in the genetic elucidation of these steroidogenic enzymes and the steroid receptors. Diverse clinical and experimental observations indicate that androgens moderate estrogenic effects on mammary proliferation and growth. Experimental data suggest The author has nothing to disclose.
    [Show full text]
  • Pediatric and Adolescent Gynecology Evidence-Based Clinical Practice Endocrine Development
    Pediatric and Adolescent Gynecology Evidence-Based Clinical Practice Endocrine Development Vol. 7 Series Editor Martin O. Savage London Pediatric and Adolescent Gynecology Evidence-Based Clinical Practice Volume Editor Charles Sultan Montpellier 48 figures, 11 in color and 34 tables, 2004 Basel · Freiburg · Paris · London · New York · Bangalore · Bangkok · Singapore · Tokyo · Sydney Prof. Dr. Charles Sultan Unité d’Endocrinologie et de Gynécologie Pédiatriques Service de Pédiatrie I Hôpital Arnaud de Villeneuve Centre Hospitalier Universitaire Montpellier, France Library of Congress Cataloging-in-Publication Data Pediatric and adolescent gynecology : evidence-based clinical practice / volume editor, Charles Sultan. p. ; cm. – (Endocrine development, ISSN 1421–7082 ; v. 7) Includes bibliographical references and index. ISBN 3–8055–7623–4 (hard cover : alk. paper) 1. Pediatric gynecology. 2. Adolescent medicine. 3. Evidence-based medicine. I. Sultan, Charles. II. Series. [DNLM: 1. Genital Diseases, Female–Adolescent. 2. Genital Diseases, Female–Child. 3. Evidence-Based Medicine. 4. Genitalia, Female–abnormalities–Adolescent. 5. Genitalia, Female–abnormalities–Child. WS 360 P37077 2004] RJ478.P433 2004 618.92Ј098–dc22 2003061930 Bibliographic Indices. This publication is listed in bibliographic services, including Current Contents® and Index Medicus. Drug Dosage. The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions.
    [Show full text]
  • Breast Concerns and Disorders in Adolescent Females
    Review Article Page 1 of 8 Breast concerns and disorders in adolescent females Donald E. Greydanus1, Lyubov Matytsina-Quinlan2 1Department of Pediatric & Adolescent Medicine, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, MI, USA; 2East Cheshire Centre for Sexual Health, East Cheshire NHS Trust, Macclesfield District General Hospital, Macclesfield, Cheshire, SK103BL, UK Contributions: (I) Conception and design: All authors; (II) Administrative support: All authors; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final Approval of manuscript: All authors. Correspondence to: Donald E. Greydanus. Department of Pediatric & Adolescent Medicine, Western Michigan University Homer Stryker M.D. School of Medicine, 1000 Oakland Drive, Kalamazoo, MI 49008-1284, USA. Email: [email protected]. Abstract: Breast disorders are an important aspect of health care for adolescent females and this discussion presents principles for education and management of breast concerns as well as problems for this population of patients. Normal and abnormal breast development are considered. Breast pathology that is reviewed include congenital lesions as well as breast asymmetry, atrophy, tuberous breasts, fibroadenoma, cystosarcoma phyllodes, benign breast disease, mastalgia and other breast disorders. Keywords: Athelia; polymastia; fibroadenoma; mastitis; mammary hyperplasia; fibrocystic change Received: 11 June 2019; Accepted: 17 June 2019; published: 03 July 2019. doi: 10.21037/pm.2019.06.07 View this article at: http://dx.doi.org/10.21037/pm.2019.06.07 Introduction a mother or other close relative has a breast cancer history. In the primary care medical practice, the adolescent female Breast disorders are an important aspect of health care may present with a number of concerns related to the size, for female adolescents (1-7).
    [Show full text]
  • Bilateral Idiopathic Granulomatous Mastitis
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Asian Journal of Surgery (2016) 39,12e20 Available online at www.sciencedirect.com ScienceDirect journal homepage: www.e-asianjournalsurgery.com ORIGINAL ARTICLE Bilateral idiopathic granulomatous mastitis Mehmet Velidedeoglu a, Fahrettin Kilic b, Birgul Mete c, Mucahit Yemisen c, Varol Celik a, Ertugrul Gazioglu a, Mehmet Ferahman a, Resat Ozaras c, Mehmet Halit Yilmaz b, Fatih Aydogan a,* a Department of General Surgery, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey b Department of Radiology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey c Department of Infectious Diseases, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey Received 1 July 2014; received in revised form 24 February 2015; accepted 25 February 2015 Available online 2 May 2015 KEYWORDS Summary Objectives: Idiopathic granulomatous mastitis (IGM) is a benign rare inflammatory breast cancer; pseudotumor. Bilateral involvement of IGM has been reported in a few cases. To our knowl- cancer; edge, this study is the largest series of bilateral cases to date. The goals of this study were corticosteroids; to present clinical features of bilateral IGM and to evaluate the results of treatments. granulomatous Materials and methods: We performed a retrospective review of the idiopathic granulomatous mastitis; mastitis database from 2010 to 2013. Ten female patients who met required histologic and clin- idiopathic; ical criteria of IGM in both breasts were included in study. Demographic data, clinical findings, tuberculosis medication history, and radiologic findings are presented. Results: The mean age at onset of the disease was 38.4 Æ 8.3 years (range: 29e52 years).
    [Show full text]
  • Patient Educational Brochure Reconstruction
    PATIENT EDUCATIONAL BROCHURE RECONSTRUCTION BREAST RECONSTRUCTION WITH SIENTRA SILICONE GEL BREAST IMPLANTS Revision Date: February 15, 2012 TABLE OF CONTENTS Glossary.................................................................................................................................................. 1 1. How To Use This Educational Brochure ..................................................................................... 12 2. General Information About Breast Reconstruction With Breast Implants .............................. 13 2.1 What Gives The Breast Its Shape? .................................................................................. 13 2.2 What Is A Silicone Gel Breast Implant? ........................................................................... 14 2.3 How Do Breast Implants Work In Breast Reconstruction? ............................................... 14 3. Deciding Whether To Have Breast Reconstruction Surgery With Implants ........................... 15 3.1 Am I Eligible For Reconstruction With Silicone Gel Breast Implants? ............................. 15 3.2 Contraindications .............................................................................................................. 16 3.3 Precautions ....................................................................................................................... 16 3.4 Warnings........................................................................................................................... 17 3.5 What Are The Alternatives To
    [Show full text]
  • Bilateral Idiopathic Granulomatous Mastitis
    + MODEL Asian Journal of Surgery (2015) xx,1e9 Available online at www.sciencedirect.com ScienceDirect journal homepage: www.e-asianjournalsurgery.com ORIGINAL ARTICLE Bilateral idiopathic granulomatous mastitis Mehmet Velidedeoglu a, Fahrettin Kilic b, Birgul Mete c, Mucahit Yemisen c, Varol Celik a, Ertugrul Gazioglu a, Mehmet Ferahman a, Resat Ozaras c, Mehmet Halit Yilmaz b, Fatih Aydogan a,* a Department of General Surgery, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey b Department of Radiology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey c Department of Infectious Diseases, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey Received 1 July 2014; received in revised form 24 February 2015; accepted 25 February 2015 KEYWORDS Summary Objectives: Idiopathic granulomatous mastitis (IGM) is a benign rare inflammatory breast cancer; pseudotumor. Bilateral involvement of IGM has been reported in a few cases. To our knowl- cancer; edge, this study is the largest series of bilateral cases to date. The goals of this study were corticosteroids; to present clinical features of bilateral IGM and to evaluate the results of treatments. granulomatous Materials and methods: We performed a retrospective review of the idiopathic granulomatous mastitis; mastitis database from 2010 to 2013. Ten female patients who met required histologic and clin- idiopathic; ical criteria of IGM in both breasts were included in study. Demographic data, clinical findings, tuberculosis medication history, and radiologic findings are presented. Results: The mean age at onset of the disease was 38.4 Æ 8.3 years (range: 29e52 years). Nine patients had no recurrence during a mean follow-up period of 21 months (range: 11e26 months).
    [Show full text]
  • 1995 © Copyright 1995 by International Lactation Consultant Association
    J Hum Lact 11(2), 1995 © Copyright 1995 by International Lactation Consultant Association. Infant Insufficient Milk Syndrome Associated with Maternal Postpartum Hemorrhage Claire Elizabeth Willis, MB, BCh, and Verity Livingstone, MB BS, IBCLC ABSTRACT - Insufficient milk syndrome is defined as failure to thrive in infants due to insufficient daily breastmilk intake. This discussion examines a possible association between insufficient milk syndrome and maternal postpartum hemorrhage. Ten consecutive cases of insufficient milk syndrome associated with maternal postpartum hemorrhage were identified. The mothers presented between 3 and 35 days postpartum. Maternal postpartum blood loss ranged from 500-1500 ml in eight cases (mean: 963 ml); in two cases, blood loss was noted as 400++ and 200++, respectively. Six mothers experienced a drop of hemoglobin by >30g/L; two had a drop in blood pressure >3OmmHg for >20 minutes. All infants were failing to thrive. Five infants suffered hypernatremic dehydration with serum sodium levels ranging from 148-l66mmol/L. Breastmilk electrolytes were measured in six cases, and elevated sodium levels, ranging from 21-l00mmol/L, in five cases. These data serve to heighten awareness of insufficient milk syndrome as a potential consequence of postpartum hemorrhage. Early postpartum review of all breast-feeding mothers and infants is strongly encouraged. JHL 11:123-126, 1995. KEYWORDS: breastfeeding, hypernatremic dehydration, insufficient milk syndrome, postpartum hemorrhage. INTRODUCTION The insufficient milk syndrome (IMS) and hence failure to thrive in breastfed neonates is an increasingly recognised problem. There may be demonstrable inadequate milk intake or it may be the mother’s perception that her milk supply is inadequate; it may be reversible or irreversible.
    [Show full text]
  • Drug-Induced Endocrinopathies and Diabetes
    2 181 E Diamanti-Kandarakis and Drug-induced endocrinopathies 181:2 R73–R105 Review others and diabetes DIAGNOSIS OF ENDOCRINE DISEASE Drug-induced endocrinopathies and diabetes: a combo-endocrinology overview E Diamanti-Kandarakis1, L Duntas2, G A Kanakis3, E Kandaraki1, N Karavitaki4,5, E Kassi6, S Livadas7, G Mastorakos8, I Migdalis9, A D Miras10, S Nader11, O Papalou1, R Poladian12, V Popovic13, D Rachoń14, S Tigas15, C Tsigos16, T Tsilchorozidou17, T Tzotzas18, A Bargiota19 and M Pfeifer20 on behalf of COMBO ENDO TEAM: 2018 1Department of Endocrinology, Diabetes and Metabolism, Hygeia Hospital, 2Endocrine Clinic Evgenidion Hospital, University of Athens, 3Department of Endocrinology, Athens Naval & VA Hospital, Athens, Unit of Reproductive Endocrinology, Athens, Greece, 4Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, 5Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK, 6Department of Biological Chemistry, First Department of Internal Medicine, Laikon Hospital Medical School, NKUA, 7Endocrine Unit, Metropolitan Hospital, 8Endocrine Unit, 2nd Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, ‘Aretaieion’ University Hospital, 9Second Medical Department and Diabetes Centre, NIMTS Hospital, Athens, Greece, 10Division of Endocrinology Diabetes and Metabolic Medicine, Imperial College London, London, UK, 11Department of Internal Medicine-Endocrine Division, McGovern Medical School, Houston, Texas, USA, 12Department of Endocrinology, MLH University Hospital, Beirut, Lebanon, 13School of Medicine, University of Belgrade, Belgrade, Serbia, 14Department of Clinical and Experimental Endocrinology, Medical Correspondence University of Gdańsk, Gdańsk, Poland, 15Department of Endocrinology, Ioannina University Hospital, Ioannina, Greece, should be addressed 16Harokopio University of Athens and HYGEIA Hospital, Athens, Greece, 17Private Practice, Endocrinologist, Serres, to E Diamanti-Kandarakis Greece, 18St.
    [Show full text]